This article has been updated from a previous version.  

NEW YORK, July 17 – Compugen licensed its Gencarta database of annotated genomic, transcription, and proteomic data to the Japanese pharmaceutical company Kyowa-Hakko Kogyo, the companies announced Tuesday.

The license, which includes access to human, mice, and rat data, is for two years and is an all-cash agreement with payments up-front each year, said Eli Mintz, president of Compugen. The company would not disclose the license fee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.